175708-57-3

Basic information

• Product Name: Glycine, N-[[4-(phenylmethoxy)phenyl]methyl]-, methyl ester
• CAS NO: 175708-57-3
• Molecular Formula: C17H19NO3
• Molecular Weight: 285.343
• Mol File: 175708-57-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Glycine, N-[[4-(phenylmethoxy)phenyl]methyl]-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Glycine, N-[[4-(phenylmethoxy)phenyl]methyl]-, methyl ester(175708-57-3)
• EPA Substance Registry System: Glycine, N-[[4-(phenylmethoxy)phenyl]methyl]-, methyl ester(175708-57-3)

Safety Data

• Hazardous Substances Data: 175708-57-3(Hazardous Substances Data)

Upstream product

• 4397-53-9 p-benzyloxybenzaldehyde 
• 5680-79-5 glycine ethyl ester hydrochloride 
• 616-34-2 methoxycarbonylmethylamine 
• 144-55-8 sodium hydrogencarbonate 

Downstream Products

• 98076-56-3 [(4-Methoxy-benzyl)-amino]-acetic Acid Tert-butyl Ester 
• 1025871-17-3 [(S)-1-{(4-Benzyloxy-benzyl)-[(2-phenyl-propylcarbamoyl)-methyl]-carbamoyl}-2-(1-trityl-1H-imidazol-4-yl)-ethyl]-carbamic acid benzyl ester 
• 1026921-30-1 [(S)-1-((4-Benzyloxy-benzyl)-{[(1-phenyl-cyclopentylmethyl)-carbamoyl]-methyl}-carbamoyl)-2-(1-trityl-1H-imidazol-4-yl)-ethyl]-carbamic acid benzyl ester 
• 209907-10-8 [(S)-1-((4-Benzyloxy-benzyl)-{[(1-phenyl-cyclobutylmethyl)-carbamoyl]-methyl}-carbamoyl)-2-(1-trityl-1H-imidazol-4-yl)-ethyl]-carbamic acid benzyl ester 
• 1026792-08-4 [(S)-1-{(4-Benzyloxy-benzyl)-[(2-ethyl-2-phenyl-butylcarbamoyl)-methyl]-carbamoyl}-2-(1-trityl-1H-imidazol-4-yl)-ethyl]-carbamic acid benzyl ester 
• 1026154-36-8 [(S)-1-{(4-Benzyloxy-benzyl)-[(2-phenyl-pentylcarbamoyl)-methyl]-carbamoyl}-2-(1-trityl-1H-imidazol-4-yl)-ethyl]-carbamic acid benzyl ester 
• 1026803-41-7 [(S)-1-{(4-Benzyloxy-benzyl)-[(2-phenyl-butylcarbamoyl)-methyl]-carbamoyl}-2-(1-trityl-1H-imidazol-4-yl)-ethyl]-carbamic acid benzyl ester 

Relevant articles and documents

SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME

The present invention relates to a novel sulfamide derivative, a pharmaceutically acceptable salt thereof and a pharmaceutical composition for upregulation of lipid metabolism comprising same as an active ingredient.

Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase

Inhibitors of protein farnesyl transferase enzymes are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating cancer, restenosis, psoriasis, endometriosis, atherosclerosis, or viral infe

C-terminal modifications of histidyl-N-benzylglycinamides to give improved inhibition of Ras farnesyltransferase, cellular activity, and anticancer activity in mice.

-